Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer

Keyphrases

• Bone Metastasis 100%
• Zoledronic Acid 100%
• Metastatic Breast Cancer 100%
• Intravenous Bisphosphonates 100%
• Solid Tumors 75%
• Bisphosphonates 75%
• Placebo 50%
• Skeletal Morbidity 50%
• Skeletal-related Events 25%
• Lung Cancer 25%
• Skeletal Complications 25%
• Orthopedic Surgery 25%
• Lung-other 25%
• Osteonecrosis 25%
• Metastasizing 25%
• Renal Disease 25%
• Bone Pain 25%
• Spinal Cord Compression 25%
• Palliative Radiotherapy 25%
• Hypercalcemia 25%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 25%
• Dose Reduction 25%
• Flu-like 25%
• Pathologic Fracture 25%
• Dental Care 25%

Medicine and Dentistry

• Zoledronic Acid 100%
• Bone Metastasis 100%
• Bisphosphonate 100%
• Metastatic Breast Cancer 100%
• Solid Malignant Neoplasm 75%
• Placebo 50%
• Dental Procedure 25%
• Prostate Cancer 25%
• Lung Cancer 25%
• Bone Necrosis 25%
• Bone Pain 25%
• Hypercalcaemia 25%
• Spinal Cord Compression 25%
• Pathologic Fracture 25%
• Flu Like Syndrome 25%
• Drug Dose Reduction 25%
• Orthopedic Surgery 25%
• Palliative Radiation Therapy 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Bone Metastasis 100%
• Zoledronic Acid 100%
• Bisphosphonic Acid Derivative 100%
• Metastatic Breast Cancer 100%
• Solid Malignant Neoplasm 75%
• Placebo 50%
• Prostate Cancer 25%
• Lung Cancer 25%
• Bone Pain 25%
• Hypercalcaemia 25%
• Spinal Cord Compression 25%
• Flu Like Syndrome 25%
• Pathologic Fracture 25%